Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Rucaparib effective as maintenance therapy following first-line platinum-based c...
Dr Bradley Monk - University of Arizona College, Tucson, USA
Rucaparib effective as maintenance therapy following first-line platinum-based chemo in ovarian cancer ( Dr Bradley Monk - University of Arizona College, Tucson, USA )
21 Jun 2022
RAGNAR study evidences efficacy and safety of erdafitinib in patients with advan...
Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France
RAGNAR study evidences efficacy and safety of erdafitinib in patients with advanced FGFR+ malignancies ( Dr Yohann Loriot - Institut Gustave Roussy, Villejuif, France )
17 Jun 2022
ASCO 2022: The latest in mRCC
Prof James Larkin, Dr Bernard Escudier, Prof Jens Bedke and Dr Toni Choueiri
ASCO 2022: The latest in mRCC ( Prof James Larkin, Dr Bernard Escudier, Prof Jens Bedke and Dr Toni Choueiri )
17 Jun 2022
ASCO 2022: Testing and diagnostics in EGFR exon 20 insertion positive NSCLC
Prof Tony Mok - Chinese University of Hong Kong, Shatin, Hong Kong
ASCO 2022: Testing and diagnostics in EGFR exon 20 insertion positive NSCLC ( Prof Tony Mok - Chinese University of Hong Kong, Shatin, Hong Kong )
15 Jun 2022
ASCO and WHO to collaborate on quality indicators for cancer facilities
Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland
ASCO and WHO to collaborate on quality indicators for cancer facilities ( Dr André Ilbawi - WHO Headquarters, Geneva, Switzerland )
14 Jun 2022
CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed...
Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain
CAR-T cell therapy targeting BCMA is highly effective for patients with relapsed/refractory multiple myeloma ( Dr Carlos Fernández De Larrea - Hospital Clínic de Barcelona, Spain )
14 Jun 2022
Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effe...
Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands
Treatment with high-dose multi-agent chemotherapy for high-risk lymphoma is effective but with significant toxicity ( Dr Martine Chamuleau - Amsterdam UMC, Amsterdam, Netherlands )
14 Jun 2022
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves surviva...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
Comment: Addition of ixazomib to pomalidomide and dexamethasone improves survival for multiple myeloma patients ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDM...
Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA
EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )
14 Jun 2022
A bispecific antibody talquetamab shows promising efficacy in relapsed/refractor...
Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands
A bispecific antibody talquetamab shows promising efficacy in relapsed/refractory multiple myeloma ( Prof Monique Minnema - University Medical Center Utrecht, Utrecht, Netherlands )
13 Jun 2022
Ponatinib and blinatumomab shows complete molecular response for patients with P...
Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA
Ponatinib and blinatumomab shows complete molecular response for patients with Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )
13 Jun 2022
Subcutaneous isatuximab administration in combination with pomalidomide-dexameth...
Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia
Subcutaneous isatuximab administration in combination with pomalidomide-dexamethasone in RRMM can improve convenience and relieve burden for patients ( Prof Hang Quach - St.Vincent’s Hospital, Sydney, Australia )
13 Jun 2022